



**EORTC-CLTG**  
ANNUAL MEETING

**2023**  
21-23 SEPTEMBER



**2023**  
THE NETHERLANDS



VENUE Burumzaal | LUMC | Leiden

## SPONSORS

### DIAMOND SPONSOR

---



Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ -years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: [www.kyowakirin.com](http://www.kyowakirin.com).

### GOLD SPONSOR

---



**Building quality cancer care together**

Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. Guided by its core values of quality, respect, and integrity, by its track record of over forty years of commercial execution, and its commitment to extending and improving the lives of cancer patients globally, Helsinn is the partner of choice for the biotech and pharma sector. With its leading position in cancer supportive care and strong focus in oncology and rare diseases, Helsinn is able to reach patients worldwide through its integrated CMC/manufacturing/supply and commercial platform complemented by scientific and technological expertise.

Helsinn has a commercial presence in 190 countries either directly, with its operating subsidiaries in the U.S. and China, or via its network of over forty long-standing trusted partners.

Please visit [www.helsinn.com](http://www.helsinn.com) - [Twitter](#) - [LinkedIn](#).



**EORTC-CLTG**  
ANNUAL MEETING

**2023**  
21-23 SEPTEMBER



**THE NETHERLANDS**



VENUE Burumazaal | LUMC | Leiden

## GOLD SPONSOR

---



**Therakos**<sup>TM</sup>  
*ECP Immunomodulation*

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. To learn more about Mallinckrodt, visit [www.mallinckrodt.com](http://www.mallinckrodt.com).

Therakos is a specialty brand of Mallinckrodt that focuses on the delivery of ECP Immunomodulation. The THERAKOS<sup>TM</sup> CELLEX<sup>TM</sup> Photopheresis System is the world's only fully integrated and validated ECP system and is used by over 300 treatment centres in over 30 countries worldwide.

Beyond the THERAKOS<sup>TM</sup> CELLEX<sup>TM</sup> Photopheresis System, we offer a comprehensive range of support services to help enable healthcare professionals (HCPs) to deliver optimised ECP immunomodulation to patients. Therakos have been crafting ECP solutions (products, services and education) since 1987.

To learn more about this product visit [www.therakos.eu](http://www.therakos.eu).

## SILVER SPONSOR

---



At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We are structured within Takeda to ensure a tight connection from research to development to commercialization and meet the needs of the cancer community, optimizing our ability to bring potentially transformative medicines to market. With demonstrated leadership in the treatment of hematologic cancers and solid tumors, we propel cutting-edge science around the power of innate immunity to enhance and broaden the impact of immunotherapy.

We complement our deep in-house expertise with symbiotic partnerships to unlock promising science wherever it emerges.

For more information: [www.takedaoncology.com](http://www.takedaoncology.com).



**EORTC-CLTG**  
ANNUAL MEETING

**2023**  
21-23 SEPTEMBER



**2023**  
THE NETHERLANDS



VENUE Burumzaal | LUMC | Leiden

BRONZE SPONSOR

---



4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: Kinselby - resminostat.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany, and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C40).

BRONZE SPONSOR

---



**FRESENIUS**  
**KABI**

caring for life

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used for the therapy and care of critically and chronically ill patients.

In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.

With its corporate mission of "caring for life", Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face.



BRONZE SPONSOR \_\_\_\_\_



Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For more information, visit [incyte.com](https://www.incyte.com) and follow [@incyte](https://twitter.com/incyte).